Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03933826 · ClinicalTrials.gov registry record
CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer
A clinical trial of Bladder Cancer and Non-muscle Invasive Bladder Cancer, sponsored by University of Washington.
- Active
- Registry status
- 570
- Enrollment target
- 20
- Study locations
NCT03933826: Active study of Bladder Cancer and Non-muscle Invasive Bladder Cancer, sponsored by University of Washington.
NCT03933826 is a study of Bladder Cancer and Non-muscle Invasive Bladder Cancer that is active but no longer recruiting, run by University of Washington. The registered enrollment target is 570 participants, below the 12,750-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03933826, a study of Bladder Cancer and Non-muscle Invasive Bladder Cancer, is active but no longer recruiting, sponsored by University of Washington.
- ACTIVE NOT RECRUITING
- Registry status
- 570 participants
- Enrollment target
- 20
- Study locations
Study Summary
Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinicians. The Comparison of Intravesical Therapy and Surgery as Treatment Options (CISTO) for Bladder Cancer Study has the potential to fill these critical evidence gaps, change care pathways for the management of non-muscle-invasive bladder cancer (NMIBC), and provide for personalized, patient-centered care. The purpose of CISTO is to conduct a large prospective study that directly compares the impact of medical management versus bladder removal in recurrent high-grade NMIBC patients with Bacillus Calmette-Guerin (BCG) failure on clinical outcomes and patient and caregiver experience using standardized patient-reported outcomes (PROs).
Primary Outcome
The primary outcome of patient-reported quality of life is measured by the EORTC QLQ-C30 Physical Function scale. The scale ranges in score from 0 to 100, with higher function scores indicating better health. Scale score is calculated by transforming individual item scores into a 0 to 1 scale, taking the mean, and multiplying by 100. Each scale requires responses for at least 50% of the items in order to be calculated.
Conditions Studied
Study Locations (20)
California
- USC/Norris Comprehensive CA Center - Los Angeles
- UCLA - Los Angeles
- Hoag Memorial Hospital Presbyterian - Newport Beach
Michigan
- Michigan Medicine Rogel Cancer Center - Ann Arbor
- Spectrum Health - Grand Rapids
- Comprehensive Urology -- A Division of Michigan Healthcare Professionals - Royal Oak
Florida
- University of Miami - Miami
- H. Lee Moffitt Cancer Center & Research Institute - Tampa
Maryland
- Johns Hopkins University, School of Medicine - Baltimore
- Chesapeake Urology Research Associates - Hanover
Alabama
- University of Alabama at Birmingham - Birmingham
Arizona
- Mayo Clinic Cancer Center - Phoenix
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Georgia
- Emory University - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 570 participants |
| Start Date | 2019-07-09 |
| Est. Completion | 2029-06-30 |
What the registry record for NCT03933826 still lists
NCT03933826 is an observational study that tracks outcomes without assigning an intervention. The registered 570 participants enrollment target is mid-sized for trials with a published cap, below the 12,750-participant average among 175 other Bladder Cancer trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Bladder Cancer appearing as the primary indexed condition, and to 0 interventions.
NCT03933826 names 20 study sites across 14 states, led by California, Michigan, Florida.
Frequently Asked Questions
What is clinical trial NCT03933826 about?
NCT03933826 is a clinical study titled "CISTO: Comparison of Intravesical Therapy and Surgery as Treatment Options for Bladder Cancer". Bladder cancer is the most common urinary tract cancer and the 5th most common cancer in the US (1). Yet bladder cancer research is underfunded relative to other common cancers. As a result, bladder cancer care is prone to evidence gaps that produce decision uncertainty for both patients and clinici...
What is the current status of trial NCT03933826?
This trial is currently active not recruiting. The enrollment target is 570 participants. The study started on 2019-07-09. Estimated completion is 2029-06-30.
What conditions does trial NCT03933826 study?
This clinical trial studies the following conditions: Bladder Cancer, Non-muscle Invasive Bladder Cancer, Cancer of the Bladder, Recurrent.
Who is sponsoring clinical trial NCT03933826?
This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03933826 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Bladder Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03933826's enrollment target sits among peer trials
570 29th of 175 higher than 147 of 175 other Bladder Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Bladder Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
RECRUITING · Phase 1
-
Home Intravenous Fluid Infusion After Undergoing Radical Cystectomy
RECRUITING · NA
-
KEYMAKER-U04 Substudy 04D: A Clinical Study of New Treatments Given With Enfortumab Vedotin and Pembrolizumab in People With Urothelial Cancer (MK-3475-04D/KEYMAKER-U04)
RECRUITING · Phase 1
-
CONFIRM: Magnetic Resonance Guided Radiation Therapy
RECRUITING · NA
-
Intravesical Treatment of Bladder Cancer at Home, Multi-modal Treatment Support
RECRUITING · NA
-
Improving Care for Rural Patients With Solid Tumors
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05000645 · 570 participants · NA
Grocery Delivery and Healthy Weight Gain Among Low-income Pregnant Young Women
- NCT06239844 · 570 participants · NA
Navigating Together for Equitable Asthma Management for Children in Families Who Communicate in Language Other Than English
- NCT06701903 · 570 participants · Phase 2
Study of ITI-1284 as Monotherapy Treatment in Patients With Generalized Anxiety Disorder
- NCT07266831 · 570 participants · Phase 2
A Clinical Study of Islatravir and Ulonivirine for People With HIV-1 Who Have Not Been Treated Before (MK-8591B-062)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI